Amneal Other Stockholder Equity from 2010 to 2024

AMRX Stock  USD 8.32  0.09  1.07%   
Amneal Pharmaceuticals, Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 463.4 M in 2024. During the period from 2010 to 2024, Amneal Pharmaceuticals, Other Stockholder Equity regression line of annual values had significance of  0.0001 and arithmetic mean of  278,371,256. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2016-12-31
Previous Quarter
545.7 M
Current Value
553.2 M
Quarterly Volatility
209.7 M
 
Covid
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Amneal Pharmaceuticals, Class over the last few years. It is Amneal Pharmaceuticals,'s Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Amneal Other Stockholder Equity Regression Statistics

Arithmetic Mean278,371,256
Coefficient Of Variation117.90
Mean Deviation310,169,207
Median8,562,000
Standard Deviation328,193,221
Sample Variance107710.8T
Range737.6M
R-Value0.83
Mean Square Error36643T
R-Squared0.68
Significance0.0001
Slope60,698,100
Total Sum of Squares1507951.1T

Amneal Other Stockholder Equity History

2024463.4 M
2023539.2 M
2022691.6 M
2021658.4 M
2020670.1 M
2019721.7 M
2018530.4 M

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity539.2 M463.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.